Amgen's New Data For Krystexxa (Pegloticase) Show A Decrease In Blood Pressure During Treatment In Chronic Gout Refractory Patients To Oral Urate-lowering Treatment − Uncontrolled Gout − Both With And Without Chronic Kidney Disease
Portfolio Pulse from Benzinga Newsdesk
Amgen has presented new data for its drug Krystexxa (Pegloticase) at the American Society Of Nephrology Kidney Week. The data shows a decrease in blood pressure during treatment in chronic gout refractory patients to oral urate-lowering treatment, both with and without chronic kidney disease.
November 02, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen's new data for Krystexxa shows promising results, potentially leading to increased usage and sales of the drug.
The new data presented by Amgen shows that Krystexxa is effective in reducing blood pressure in chronic gout patients. This could lead to increased usage of the drug, especially in patients with chronic kidney disease, and therefore potentially increase sales for Amgen.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100